CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO


10-April-2012
A Certified Spiking Solution® of Carbamazepine-10,11-epoxide is now available.


Carbamazepine-10,11-epoxide, C-121
1.0 mg/mL in Methanol

Carbamazepine-10,11-epoxide is the primary, active metabolite in both urine and serum of carbamazepine, an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder as well as trigeminal neuralgia. Potential toxicity of the epoxide metabolite requires regular therapeutic drug monitoring by LC or LC/MS for patients taking carbamazepine.

In the coming months Cerilliant will introduce a Certified Spiking Solution® of the newer anticonvulsant drug Lacosamide. Lacosamide, marketed under the trade name Vimpat®, was approved for sale in the US on October 29, 2008, for the treatment of partial-onset seizures and diabetic neuropathic pain.



Cerilliant Certified Solution Standards and Certified Spiking Solutions are manufactured to the highest industry standards. We are accredited to ISO Guide 34 and ISO/IEC 17025 & certified to ISO 13485 and ISO 9001. Our quality system also incorporates cGMP and GLP requirements


All New Product Announcements


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn